Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma (Nature, (2022), 611, 7934, (155-160), 10.1038/s41586-022-05368-8)

Rodabe N. Amaria, Michael Postow, Elizabeth M. Burton, Michael T. Tetzlaff, Merrick I. Ross, Carlos Torres-Cabala, Isabella C. Glitza, Fei Duan, Denái R. Milton, Klaus Busam, Lauren Simpson, Jennifer L. McQuade, Michael K. Wong, Jeffrey E. Gershenwald, Jeffrey E. Lee, Ryan P. Goepfert, Emily Z. Keung, Sarah B. Fisher, Allison Betof-Warner, Alexander N. ShoushtariMargaret Callahan, Daniel Coit, Edmund K. Bartlett, Danielle Bello, Parisa Momtaz, Courtney Nicholas, Aidi Gu, Xuejun Zhang, Brinda Rao Korivi, Madhavi Patnana, Sapna P. Patel, Adi Diab, Anthony Lucci, Victor G. Prieto, Michael A. Davies, James P. Allison, Padmanee Sharma, Jennifer A. Wargo, Charlotte Ariyan, Hussein A. Tawbi

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Fingerprint

Dive into the research topics of 'Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma (Nature, (2022), 611, 7934, (155-160), 10.1038/s41586-022-05368-8)'. Together they form a unique fingerprint.

Medicine & Life Sciences